Moderna Inc (MIL:1MRNA)
€ 38.165 -0.445 (-1.15%) Market Cap: 14.61 Bil Enterprise Value: 9.32 Bil PE Ratio: 0 PB Ratio: 1.30 GF Score: 44/100

Moderna Inc at Goldman Sachs Global Healthcare Conference Transcript

Jun 12, 2019 / 09:00PM GMT
Salveen Jaswal Richter
Goldman Sachs Group Inc., Research Division - VP

Good afternoon. Thanks, everyone, for joining us. I'm Salveen Richter, one of the biotech technology analysts at Goldman Sachs. And we're pleased to have the team from Moderna here today. We have Stéphane Bancel, CEO; and Lorence Kim, CFO.

Questions & Answers

Salveen Jaswal Richter
Goldman Sachs Group Inc., Research Division - VP

So maybe to start, just given your recent IPO, could you just provide us with a brief overview of the company, the mRNA technology and your modality approach to drug development?

StÃ;phane Bancel
Moderna, Inc. - CEO & Director

© -

Okay. Good. So thank you so much for having us today. So Moderna, as many of you know, are using messenger RNA to make medicine inside people's body. We believe this is a new class of medicine that provides a very large product opportunity, because to further the protein coding in the human genome are not [drug-able] using recombinant technology. Because it's a

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot